Watch SXTPW. Know when insiders buy.
One email the day a filing lands. Free.
SXTPW
60 DEGREES PHARMACEUTICALS, INC.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM $1.1M +73.2%NET INCOME −$8.1MNET CASH $873K52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $208K | +106.0% | 27.3% | −$2.3M | −$2.3M | — | -0.90 | −$2.2M | $0 | −$2.2M | Aug 14 |
| Q1 2026 · Mar 31 | $162K | −0.9% | 47.1% | −$2.1M | −$2.1M | — | -1.28 | −$2.7M | $30K | −$2.8M | May 15 |
| Q4 2025 · Dec 31derived | $303K | +25.6% | 60.2% | −$1.9M | −$1.4M | — | -7.08 | −$1.7M | $80K | −$1.8M | Mar 30 |
| Q3 2025 · Sep 30 | $438K | +223.4% | -22.9% | −$2.3M | −$2.3M | — | -0.66 | −$2.1M | $10K | −$2.1M | Nov 13 |
| Q2 2025 · Jun 30 | $101K | −19.2% | 50.4% | −$1.6M | −$1.7M | — | -5.01 | −$1.5M | $47K | −$1.5M | Aug 14 |
| Q1 2025 · Mar 31 | $164K | +54.8% | 55.2% | −$1.9M | −$1.9M | −535.9% | -6.25 | −$1.6M | $3K | −$1.6M | May 15 |
| Q4 2024 · Dec 31derived | $242K | +92.3% | 51.1% | −$2.1M | −$2M | — | -52.43 | −$1.6M | $0 | −$1.6M | Mar 30 |
| Q3 2024 · Sep 30 | $135K | +164.3% | 17.4% | −$2.1M | −$2.2M | −151.6% | -2.92 | −$1.7M | $14K | −$1.7M | Nov 13 |
| Q2 2024 · Jun 30 | $125K | — | 28.3% | −$4.2M | −$4.2M | — | -21.12 | −$1.2M | — | — | Aug 13 |
| Q1 2024 · Mar 31 | $106K | — | 38.1% | −$1.3M | $430K | — | 1.83 | −$1.1M | — | — | May 15 |
| Q4 2023 · Dec 31derived | $126K | — | -16.4% | −$1.9M | −$2M | — | -52.59 | −$64K | $56K | −$119K | Mar 27 |
| Q3 2023 · Sep 30 | $51K | — | -39.1% | −$1.5M | $4.2M | — | 9.13 | −$3.8M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1M | 22.3% | −$7.8M | −$7.4M | -732.5% | -11.73 | −$6.8M | $140K | −$7M | — | — |
| FY2024 · to Dec 31 | $608K | 36.7% | −$9.7M | −$7.9M | -1308.0% | -74.17 | −$5.6M | $104K | −$5.8M | — | — |
| FY2023 · to Dec 31 | $254K | -87.1% | −$5.2M | −$3.8M | -1485.1% | -59.18 | −$4.5M | $58K | −$4.6M | — | — |
| FY2022 · to Dec 31 | $223K | -93.7% | −$1.8M | −$6.2M | -2769.5% | -2.61 | −$1M | — | — | — | — |
Every number comes from 60 DEGREES PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.